These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 16691065

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A, Sawyer W.
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM, Bonjoch A, Iribarren J, Galindo MJ, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B, HIV Conference Call Study Group.
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [Abstract] [Full Text] [Related]

  • 9. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [Abstract] [Full Text] [Related]

  • 10. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Feb; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Møller N, Weber J, Horban A, Staszewski S, Lundgren JD, Phillips AN, EuroSIDA Study Group.
    AIDS; 2005 Feb 18; 19(3):319-30. PubMed ID: 15718843
    [Abstract] [Full Text] [Related]

  • 13. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, Swiss HIV Cohort Study.
    Clin Infect Dis; 2008 Oct 15; 47(8):1093-101. PubMed ID: 18783328
    [Abstract] [Full Text] [Related]

  • 14. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB, Berrisford AE, Boulle AM.
    Pediatr Infect Dis J; 2008 Nov 15; 27(11):993-8. PubMed ID: 18818556
    [Abstract] [Full Text] [Related]

  • 15. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodés B, Casas E, González-Lahoz J.
    J Hum Virol; 1999 Nov 15; 2(6):344-9. PubMed ID: 10774551
    [Abstract] [Full Text] [Related]

  • 16. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
    Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J, Knysz B, Phillips AN, Mocroft A, EuroSIDA Study Group.
    Antivir Ther; 2006 Nov 15; 11(6):707-15. PubMed ID: 17310815
    [Abstract] [Full Text] [Related]

  • 17. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Nov 15; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 18. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S.
    AIDS; 2006 Oct 03; 20(15):1951-4. PubMed ID: 16988516
    [Abstract] [Full Text] [Related]

  • 19. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
    Winston A, McAllister J, Amin J, Cooper DA, Carr A.
    HIV Med; 2005 May 03; 6(3):191-7. PubMed ID: 15876286
    [Abstract] [Full Text] [Related]

  • 20. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S, Yeni PG, Bouchaud O, Costagliola D, Clinical Epidemiology Group from the French Hospital Database on HIV.
    AIDS; 2006 Oct 24; 20(16):2099-106. PubMed ID: 17053356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.